Preclinical Imaging Market Expansion Outlook: $4.81 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Preclinical Imaging Market By 2029?

The preclinical imaging market size has experienced substantial growth in recent years. This market is forecast to increase from $3.46 billion in 2024 to $3.69 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed in the past can be ascribed to government initiatives, the rising prevalence of diseases, widening applications, enhanced awareness, and the growth of emerging markets.

The preclinical imaging market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $4.81 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.9%. This forecasted growth can be attributed to the adoption of personalized medicine, progress in molecular imaging, the outsourcing of drug development processes, supportive regulatory measures, and the increasing prevalence of chronic diseases. Prominent developments expected during this period include the introduction of green imaging technologies, continuous technological advancements, an uptick in research and development activities, strategic collaborations and partnerships, and the integration of real-time imaging capabilities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12393&type=smp

Which Drivers Are Shaping The Preclinical Imaging Industry’s Market Share?

The projected expansion of the preclinical imaging market is significantly influenced by the rising prevalence of chronic conditions. These are defined as enduring health issues that persist over a prolonged duration, generally exceeding three months. Such conditions frequently necessitate continuous medical care and can substantially diminish an individual’s quality of life. Preclinical imaging instruments are employed to identify chronic diseases through visualization of bone structure and lung function. Additionally, these tools aid in the study of chronic diseases, allowing for the visualization of disease progression and enhancing comprehension. For example, data from the World Health Organization (WHO) 2022 Highlights, published in September 2022 by the Switzerland-based intergovernmental health organization, indicated that Noncommunicable diseases (NCDs), or chronic diseases, were responsible for 41 million deaths annually worldwide, accounting for 74% of all fatalities. Specifically, these included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the growing incidence of chronic diseases is a primary catalyst for the expansion of the preclinical imaging market.

How Is The Preclinical Imaging Market Segmented?

The preclinical imagingmarket covered in this report is segmented –

1) By Modality: Optical Imaging Systems; Preclinical Nuclear Imaging Systems; Micro-Magnetic Resonance Imaging Systems; Micro-Ultrasound Systems; Micro-Computed Tomography Systems; Preclinical Photoacoustic Imaging Systems; Preclinical Magnetic Particle Imaging (MPI) Systems

2) By Reagents: Preclinical Optical Imaging Reagents; Preclinical Nuclear Imaging Reagents; Preclinical MRI Contrast Agents; Preclinical Ultrasound Contrast Agents; Preclinical CT Contrast Agents

3) By End User: Hospital; Diagnostics Center; Other End-User

Subsegments:

1) By Optical Imaging Systems: Bioluminescence Imaging; Fluorescence Imaging

2) By Preclinical Nuclear Imaging Systems: Positron Emission Tomography (PET); Single-Photon Emission Computed Tomography (SPECT)

3) By Micro-Magnetic Resonance Imaging (Micro-MRI) Systems: High-Resolution Micro-MRI Systems; Functional Micro-MRI Systems

4) By Micro-Ultrasound Systems: High-Frequency Ultrasound Imaging; Real-Time Micro-Ultrasound Systems

5) By Micro-Computed Tomography (Micro-CT) Systems: In Vivo Micro-CT Systems; Ex Vivo Micro-CT Systems

6) By Preclinical Photoacoustic Imaging Systems: Multi-Wavelength Photoacoustic Imaging; Hybrid Photoacoustic Imaging Systems

7) By Preclinical Magnetic Particle Imaging (MPI) Systems: MPI For Cell Tracking; MPI For Vascular Imaging

What Long-Term Trends Will Shape The Future Growth Of The Preclinical Imaging Industry?

Product innovations are emerging as a significant trend in the preclinical imaging market, with leading companies actively developing advanced products to maintain their market standing. For instance, in May 2022, Fujifilm VisualSonics Inc., a Canada-based biomedical firm specializing in imaging systems, launched the Vevo F2 for preclinical imaging. This groundbreaking product represents the first preclinical ultra-high- to low-frequency (71 MHz–1 MHz) ultrasonic and photoacoustic imaging system. The Vevo F2 integrates HD image processing technology and a completely new signal pathway, contributing to superior image clarity and improved frame rates. Additionally, the system offers customization to meet specific imaging precision requirements. Its features also include HD image processing technology, a completely new signal pathway, customizable system architecture, compatibility with a wide range of anatomical targets, and high-resolution imaging, making it suitable for diverse research applications.

Who Are The Key Multinational Companies Dominating The Preclinical Imaging Market?

Major companies operating in the preclinical imaging market include Thermo Fisher Scientific Inc., FUJIFILM Visualsonics Inc., Konica Minolta Inc., Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Miltenyi Biotech, Sofie Biosciences Inc., Promega Corporation, Ion Beam Applications S.A, Nihon Kohden, Piramal Enterprises Ltd, LI-COR Biosciences Inc., Aspect Imaging Ltd, Capintec Inc., Spectral Instruments Inc., Mediso Ltd, MR Solutions Ltd, Biospace Lab S. A., Scintica Instrumentation Inc., Trifoil Imaging, Bioscan Inc., CytoSMART Technologies B.V, Inviscan SAS, Kubtec X-ray, MILabs B.V., SCANCO Medical AG, Cristal Therapeutics.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Preclinical Imaging Market?

North America was the largest region in the preclinical imaging market in 2024. The regions covered in the preclinical imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Preclinical Imaging Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12393&type=smp

Browse Through More Reports Similar to the Global Preclinical Imaging Market 2025, By The Business Research Company

3D Medical Imaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/3d-medical-imaging-devices-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Breast Imaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795